Takeda Pays Big For De-Risked HutchMed CRC Drug

The Japanese pharma agreed to pay $400m up front plus up to $730m in milestones for a colorectal cancer drug already on the market in China and nearing regulatory filings in the US, EU and Japan.

Gold Dollars
Takeda paid substantial upfront cash for the HutchMed drug • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd. likes the de-risked status of the VEGF inhibitor it has licensed from HUTCHMED (China) Limited as well as the potential the drug offers to expand its global cancer franchise for solid tumors, particularly colorectal cancer, a Takeda exec told Scrip. The Japanese pharma announced on 23 January that it had acquired global development and commercial rights to fruquintinib, except for China, from HutchMed for $400m up front.

HutchMed – previously known as Hutchison China Meditech Ltd. (Chi-Med) – was among the Chinese biotechs that outlined plans in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.